公开(公告)号：US20160220554A1

公开(公告)日：2016-08-04

申请号：US14843480

申请日：2015-09-02

Applicant: Exelixis, Inc.

Inventor： David C. Smith ,  Maha Hussain

IPC: A61K31/47

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.

Abstract translation: 本发明涉及用MET和VEGF的双重抑制剂治疗癌症，特别是去势抗性前列腺癌和成骨细胞骨转移瘤。

公开(公告)号：US20140057908A1

公开(公告)日：2014-02-27

申请号：US13876306

申请日：2011-09-26

Applicant: Exelixis, Inc.

Inventor： David C. Smith ,  Maha Hussain

IPC: C07D215/22

CPC classification number: C07D215/22 ,  A61K31/47 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.